title: Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA.
abstract: Widespread diversion of antiretroviral (ARV) medications to illicit markets has recently been documented among indigent patients in South Florida. The recent approval of ARVs for pre-exposure prophylaxis (PrEP) has the potential to broaden these illicit markets, as high-risk individuals seek ARVs without a prescription or medical supervision. Nonadherence among diverters and unsupervised use of ARVs for treatment or PrEP increase risks of treatment failure, drug resistance, and disease transmission. We report the scope of ARV diversion among substance-using men who have sex with men in South Florida. Structured interviews (N = 515) queried demographics, HIV status, mental distress, substance dependence, and sexual risks. HIV-positive participants answered questions about medical care, treatment, and ARV adherence and diversion. Median age was 39. Of 46.4% who were HIV-positive, 79.1% were prescribed ARVs. Of these, 27% reported selling/trading ARVs. Reasons for diversion were sharing/trading with friends, sale/trade for money/drugs, and sale/trade of unused medications. ARV diverters, compared to nondiverters, were more likely to be substance dependent (74.5% vs. 58.7%, p = 0.046) and have traded sex for money/drugs (60.8% vs. 32.6%, p < 0.001), and less likely to be adherent to ARVs (54.9% vs. 73.9%, p = 0.012). ARV diversion should be a particular concern in communities of high-risk men who have sex with men as uninfected men in such communities are likely to benefit most from PrEP but unlikely to have access to PrEP and necessary ancillary services through the health-care system. The implications of diversion for increased risks of treatment failure, disease transmission, and PrEP failure should be carefully considered in developing policy and behavioral supports to scaling up treatment as prevention and PrEP.
authors.affiliation: a Center for Applied Research on Substance Use and Health Disparities , Nova Southeastern University , Miami , FL , USA.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Kurtz
authors.forename: Mance E
authors.initials: ME
authors.lastname: Buttram
authors.forename: Hilary L
authors.initials: HL
authors.lastname: Surratt
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use*; D003132:Commerce / Q000191:economics*; D005431:Florida / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D018451:Homosexuality, Male; D006801:Humans; D007407:Interviews as Topic; D008297:Male; D055118:Medication Adherence; D001523:Mental Disorders / Q000453:epidemiology; D008875:Middle Aged; D056990:Post-Exposure Prophylaxis; D012309:Risk-Taking; D012959:Socioeconomic Factors; D019966:Substance-Related Disorders / Q000150:complications / Q000453:epidemiology; D011795:Surveys and Questionnaires; D047568:Unsafe Sex; D035862:Vulnerable Populations / Q000523:psychology / Q000706:statistics & numerical data*; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents
references.citation: Subst Use Misuse. 2006;41(2):255-64
references.pmid: 16393746
references.citation: MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9
references.pmid: 22874836
references.citation: Am J Prev Med. 2013 Jan;44(1 Suppl 2):S137-40
references.pmid: 23253755
references.citation: PLoS One. 2012;7(3):e33119
references.pmid: 22470438
references.citation: Am J Prev Med. 2013 Jan;44(1 Suppl 2):S163-6
references.pmid: 23253761
references.citation: MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8
references.pmid: 21270743
references.citation: AIDS. 2001 Jun 15;15(9):1181-3
references.pmid: 11416722
references.citation: Am J Public Health. 2013 Jun;103(6):1026-8
references.pmid: 23597362
references.citation: J Acquir Immune Defic Syndr. 2010 Oct;55(2):e14-6
references.pmid: 20859085
references.citation: J Int AIDS Soc. 2012 Apr 26;15(2):17357
references.pmid: 22713254
references.citation: J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):241-7
references.pmid: 18340656
references.citation: Ann Intern Med. 2012 Apr 17;156(8):541-50
references.pmid: 22508731
references.citation: AIDS. 2010 Oct;24 Suppl 4:S27-39
references.pmid: 21042050
references.citation: J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):77-83
references.pmid: 19295337
references.citation: Pain Med. 2007 Mar;8(2):171-83
references.pmid: 17305688
references.citation: Clin Infect Dis. 2011 Dec;53(12):1265-70
references.pmid: 21976467
references.citation: Am J Prev Med. 2013 Jan;44(1 Suppl 2):S91-8
references.pmid: 23253769
references.citation: Lancet Infect Dis. 2013 Jan;13(1):10-2
references.pmid: 23257221